Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Under Scrutiny, Some Telehealth Firms Are Rethinking ADHD Drugs

May 5, 2022, 10:00 AM

The largest online mental health startup has tightened its prescription practices after criticism by medical professionals that its aggressive social-media marketing and workplace culture made some addictive medications too easy to get. And there are signs that scrutiny of mental telehealth is only intensifying.

On Wednesday, SoftBank-financed Cerebral announced it would stop writing new prescriptions for drugs that treat attention deficit/hyperactivity disorder, such as Adderall and Ritalin. That announcement came after a recently departed executive alleged in a lawsuit that Cerebral’s chief medical officer had told employees the company’s goal was to prescribe stimulants to 100% of its ADHD ...